Comparison of Gadobenate Dimeglumine and Gadopentetate Dimeglumine: A Study of MR Imaging and Inductively Coupled Plasma Atomic Emission Spectroscopy in Rat Brain Tumors

References

1. ↵
   Giovagnonia A, Paci E. Liver III: gadolinium based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/diemeg). Magn Reson Clin North Am 1996;4:61–72
2. ↵
   Gianfranco R, Gianpaolo P, Alberto S. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29(suppl 2):S183–S185
3. Riccardo M, Giulia M, Richard LB, et al. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 1999;9:704–710

   CrossRefPubMed
4. ↵
   Kuwatsuru R, Kadoya M, Ohtomo K, et al Clinical late phase III trials of multihance (Gd-BOPTA) for the magnetic resonance imaging of liver tumor in Japan. J Comput Assist Tomogr 1999;23(suppl 1):S65–S74
5. ↵
   Spinazzi A, Lorusso V, Pirovano G, et al. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282–291

   CrossRefPubMed
6. ↵
   Kstdutani N, Sagami F, Tirone P, Morisetti A, Bussi S, Mandella RC. General toxicity study of gadobenate dimeglumine formulation (E7155) (4): 4-week repeated dose intravenous toxicity study followed by 4-week recovery period in dogs. J Toxicol Sci 1999;24(suppl 1):S41–S60
7. ↵
   Okuda Y, Sagami F, Tirone P, Morisetti A, Bussi S, Masters RE. Reproductive and developmental toxicity study of gadobenate dimeglumine formulation (E7155)(4): study of embryo-fetal toxicity in rabbits by intravenous administration. J Toxicol Sci 1999;24(suppl 1):S79–S87
8. ↵
   Mascalchi M, Jin XN, Agen C, et al. Ex-vivo MR imaging of liver intracellular contrast agents. Magn Reson Imaging 1997;15:469–474

   PubMed
9. ↵
   Khokhlov VF, Yashkin PN, Silin DI, Djorova ES, Lawaczeck R. Neutron capture therapy with Gd-DTPA in tumor-bearing rats. In: Mishima Y, ed. Cancer Neutron Capture Therapy. New York, NY: Plenum Press; 1996:865–869
10. Matsumura A, Shibata Y, Nakagawa K, et al. Boron-, gadolinium-porphyrin derivatives for neutron capture therapy. In: Mishima Y, ed. Cancer Neutron Capture Therapy. New York, NY: Plenum Press; 1996;245–251
11. Hofmann B, Fischer C-O, Lawaczeck R, Platzek J, Semmler W. Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumor with the MRI contrast agent Gadobutrol. Invest Radiol 1999;34:126–133

    CrossRefPubMed
12. Akine Y, Tokita N, Tokuuye K, et al. Suppression of rabbit VX-2 subcutaneous tumor growth by gadolinium neutron capture therapy. Jpn J Cancer Res 1993;84:841–843

    PubMed
13. Akine Y, Tokita N, Tokuuye K, Satoch M, Kobayashi T, Kanda K. Electron-equivalent dose for the effect of gadolinium neutron capture therapy on the growth of subcutaneously-inoculated Ehrlich tumor cells in mice. Jpn J Clin Oncol 1993;23:145–148

    Abstract/FREE Full Text
14. ↵
    Akine Y, Tokita N, Matsumoto T, Oyama H, Egawa S, Aizawa O. Radiation effect of gadolinium neutron capture reactions on survival of Chinese hamster cells. Strahlenther Onkol 1990;166:831–833

    PubMed
15. ↵
    Pascolo L, Capelli F, Anelli PL, et al. Molecular mechanisms for hepatic uptake of magnetic resonance imaging contrast agent. Biochem Biophys Res Comm 1999;257:746–7

    CrossRefPubMed